Successful Management of Tendinopathy With Injections of the MMP-inhibitor Aprotinin
Aprotinin is a broad spectrum proteinase inhibitor (including matrix metalloproteinase [MMP] inhibitor) used for treating patellar and Achilles tendinopathies. One previous randomized control trial demonstrated aprotinin injections superior to both corticosteroid and saline injections in patellar tendinopathy (Level II), whereas results reported for aprotinin treatment in Achilles tendinopathy have been mixed. We performed a case review and followup questionnaire for 430 consecutive patients with tendinopathy treated by 997 aprotinin injections (30,000 KIU). A response rate of 72% was achieved with a minimum followup of 3 months (average, 12.2 months; range, 3–54 months). Seventy-six percent of patients had improved, 22% of patients reported no change, and 2% were worse. Sixty-four percent of patients thought aprotinin injections were helpful, while 36% believed they had neither a positive nor negative effect. Mid-Achilles tendinopathy patients (84% improvement) were more successfully treated than patellar tendinopathy patients (69% improvement). Despite stronger published evidence of benefit in patellar tendinopathy, clinical outcomes appeared better with aprotinin use in Achilles tendinopathies.
Level of Evidence: Level IV, case series. See the Guidelines for Authors for a complete description of levels of evidence.
KeywordsAprotinin Achilles Tendon Bovine Spongiform Encephalopathy Achilles Tendinopathy Rugby League
- 3.Aubin F, Javaudin L, Rochcongar P. Case report of aprotinin in Achilles tendinopathies with athletes [in French]. J Pharmacie Clinique. 1997;16:270–273.Google Scholar
- 8.Brukner P, Khan K. Clinical Sports Medicine, 3rd ed. McGraw-Hill: Sydney; 2006.Google Scholar
- 9.Capasso G, Maffulli N, Testa V, Sgambato A. Preliminary results with peritendinous potease inhibitor injections in the management of Achilles tendinitis. J Sports Traumatol Rel Res. 1993;15:37–40.Google Scholar
- 10.Capasso G, Testa V, Maffulli N, Bifulco G. Aprotinin, corticosteroids and normosaline in the management of patellar tendinopathy in athletes: a prospective randomized study. Sports Exerc Injury. 1997;3:111–115.Google Scholar
- 16.Davis G, Pintar Allen KA, Salazar R, Maxwell SA. Matrix metalloproteinase-1 and -9 activation by plasmin regulates a novel endothelial cell-mediated mechanism of collagen gel contraction and capillary tube regression in three-dimensional collagen matrices. J Cell Sci. 2001;114:917–930.PubMedGoogle Scholar
- 19.Dollery C, ed. Therapeutic Drugs. Edinburgh UK: Churchill Livingstone; 1991.Google Scholar
- 20.Druce J, Locarnini S, Birch C. Isolation of HIV-1 from experimentally contaminated multidose local anaesthetic vials. Med J Aus. 1995;162:513–515.Google Scholar
- 22.Genety J, Pernin E. Utilisation du Zymofren® dans le traitement des tendinites chez le sportif. Cahiers Méd Lyonnais. 1971;47:135–139.Google Scholar
- 34.National Health and Medical Research Council Web site. National Statement on Ethical Conduct in Human Research. Available at: http://www.nhmrc.gov.au/publications/synopses/_files/e72.pdf. Accessed June 4, 2007.
- 35.Orchard J, Hofman J, Brown R. The risks of local aprotinin injections for treating chronic tendinopathy. Sport Health. 2005;23:24–28.Google Scholar
- 36.Orchard J, Massey A, Rimmer J, Hofman J, Brown R. Delay of 6 weeks between aprotinin injections for tendinopathy reduces risk of allergic reaction. J Sci Med Sport. 2007: Aug 11 epub ahead of print.Google Scholar